Why the study?
Beta-blockers have long been the cornerstone of medical therapy for obstructive hypertrophic cardiomyopathy without disease-modifying effects, prompting evaluation of cardiac myosin inhibitors as potential monotherapy or first-line alternatives.
Do cardiac myosin inhibitors improve exercise tolerance and LVOT obstruction compared to beta-blockers in patients with obstructive hypertrophic cardiomyopathy?
Population
Patients with obstructive hypertrophic cardiomyopathy
Comparison
Cardiac myosin inhibitors vs beta-blockers
Key result
Cardiac myosin inhibitors as monotherapy demonstrated superior efficacy compared to beta-blockers in improving exercise tolerance and reducing outflow tract obstruction in obstructive HCM.
Authors
Loading...
Supports first-line CMI monotherapy in oHCM; challenges beta-blockers as standard initial therapy.
Do cardiac myosin inhibitors improve exercise tolerance and LVOT obstruction compared to beta-blockers in patients with obstructive hypertrophic cardiomyopathy?
Cardiac myosin inhibitors represent a paradigm shift in oHCM management, offering superior improvements in exercise capacity and hemodynamics compared to traditional beta-blockers, potentially positioning them as first-line therapy.
Grupper et al. (2026) studied this question. Cardiac myosin inhibitors as monotherapy demonstrated superior efficacy compared to beta-blockers in improving exercise tolerance and reducing outflow tract obstruction in obstructive HCM.